The latest data on childhood immunisation coverage by Primary Health Network (PHN) is now available for the period 1 April 2020 – 31 March 2021.
In Central and Eastern Sydney PHN, coverage rates have improved for the 1 year old and 2 year old cohorts. See data for all children March 2021 annualised data and data for children in our region CESPHN coverage rates. COVID-19 Vaccine Rollout Update
National Cabinet agreed to a recalibrated model of the COVID-19 Vaccination Rollout Strategy to account for the updated ATAGI advice, that Pfizer be the preferred vaccine for people under 50.
This model includes bringing forward access for eligible individuals aged 50 to 69.
From 3 May 2021: people 50 years and over can receive the AstraZeneca vaccine at General Practice Respiratory Clinics and state and territory vaccination clinics.
From 17 May 2021: people 50 years and over can receive the AstraZeneca vaccine at a participating general practice.
General practices can apply to the Australian Government Department of Health to begin vaccinating the over 50’s population earlier through their PHN by emailing email@example.com
After this date Zostavax will only be funded for people 70 years of age, and people aged 71 years and over will be required to purchase the vaccine privately.
Who should be vaccinated?
Identify and contact eligible patients aged 71 to 79 years using your data extraction tools PenCAT or POLAR. For assistance, contact your digital health officer at firstname.lastname@example.org
Who should not be vaccinated?
People who are immunocompromised due to disease or medication, pregnant women, and those who have previously had anaphylaxis to any VZV-containing vaccine or its components should not receive the zoster vaccine.
AusVaxSafety has monitored the safety of influenza vaccines administered to Australians of all ages since 2017. Since then, over 477,000 individuals or their parent/carer have provided details about any adverse events experienced after influenza vaccination.
Parent-friendly influenza vaccination resources from SKAI
Influenza vaccination resources for parents are available from Sharing Knowledge About Immunisation (SKAI). Written specifically for parents, the resources are designed to support their influenza vaccination information needs and guide them in their decision to vaccinate.
Administration & Timing of COVID-19 and other vaccines
Routine co-administration of a COVID-19 vaccine on the same day as another vaccine is not recommended:
There should be a minimum interval of 14 days between receipt of a COVID-19 vaccine and any other vaccine, whether live or non-live.
If a COVID-19 vaccine has inadvertently been administered on the same day or within 14 days before or after other vaccines, no vaccine doses need to be repeated.
Although immune interference is unlikely between vaccines that do not contain common antigens, there are currently no immunogenicity or safety data on co-administration of COVID-19 vaccines with other vaccines.
Shortening of the interval between COVID-19 vaccine and another vaccine:
An individual risk–benefit assessment is necessary to consider shortening of the interval between, or offer same day administration of, a COVID-19 vaccine with another vaccine.
This may be considered if there is a high risk of imminent exposure to the vaccine-targeted disease, or it is highly likely that the opportunity of receiving either vaccine will be missed.
If same day or reduced-interval vaccination is proposed, patients should be counselled about the possible adverse events from each vaccine and advised to report adverse events.
The recommended interval between two doses of COVID-19 Vaccine AstraZeneca is 12 weeks.
Shortening the interval from 12 weeks (to no less than 4 weeks) between doses is acceptable and may be appropriate in certain circumstances such as imminent travel, anticipated risk of COVID-19 exposure, etc.
The minimum interval and recommended interval between doses:
If a dose has been inadvertently given before the minimum 4-week interval, it is not currently recommended that the vaccine dose be repeated.
If the second dose of COVID-19 Vaccine AstraZeneca is administered later than the recommended 12-week interval, no vaccine doses need to be repeated.
On the basis of currently available information, Comirnaty and COVID-19 Vaccine AstraZeneca are not considered interchangeable:
The two-dose course should be completed with the same vaccine.
There are no data yet on the efficacy of mixed schedules.
If an individual develops anaphylaxis or a severe allergic reaction after the first dose of a COVID-19 vaccine, an alternate brand can be considered for the second dose. If an alternate brand is used for the second dose, a third dose of COVID-19 vaccine does not need to be given.
COVID-19 vaccine updates for GPs
Join the latest COVID-19 vaccine live stream update for GPs.
The panel will provide latest key updates and answer participants’ questions live about the COVID-19 vaccine rollout.
This webinar discusses updates on the Australian Government COVID-19 vaccine roll out plan and what this means for immunisation providers, information on thrombosis with thrombocytopenia syndrome (TTS) and AstraZeneca COVID-19 Vaccine, and practical strategies for communicating with your patients to increase vaccine acceptance and uptake.
Welcome to our new website! As you may have noticed, our website looks different. Central and Eastern Sydney PHN have moved to a new site and although much has remained the same, we have introduced some new functions. These include: Updated navigation When you land on our new website, you…
COVID-19 weekly update – 02 JANUARY 2023 COVID-19 cases in the region Please note: From next week the latest COVID-19 information will be included in the Sydney Health Weekly newsletter, rather than separated at the top. We will still provide COVID-19 related information as well as the dedicated COVID-19 latest…
FIVE QUESTIONS is where we ask members of the community to talk about how they stay HEALTHY. Randwick scientist and grandmother Hilda Stender shared this: What exercise did you do yesterday? I’ve had two knee replacements – one four years ago and the other six months ago. As a result,…
Immunisation weekly update – 1 February 2023 Childhood immunisation overdue reports CESPHN is inviting general practices to sign up to receive a regular report extracted on your behalf from the Australian Immunisation Register (AIR) which is specific to your practice. This report contains all children aged 0-5 living in the CESPHN region…
Australian Digital Health Agency (ADHA) digital health webinars Implementing MyHealth Record Policies in your organisation Thu 9 Feb 23, 12.30-1.00 pm – learn how to implement and maintain a My Health Record Security and Access policy in your organisation. Understand the importance of the Responsible Officer (RO) and Organisational Maintenance…
UNSW research – Palliative care and intellectual disability A research team led by Professor Julian Trollor at the Department of Developmental Disability Neuropsychiatry, UNSW Sydney, aims to design, implement, and evaluate a new palliative care service for people with intellectual disability. This is important because people with intellectual disability often…
GP support needed: Shared e-Care plan study for follow-up of colorectal and breast cancers This research evaluates shared care using a new interactive e-care plan being implemented through cancer services in Prince of Wales and St George public and private hospitals. Through the e-care plan GPs, cancer specialists and patients…